BETHKIS Drug Patent Profile

Which patents cover Bethkis, and what generic alternatives are available?

Bethkis is a drug marketed by Chiesi and is included in one NDA.

The generic ingredient in BETHKIS is tobramycin. There are eighteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the tobramycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bethkis

A generic version of BETHKIS was approved as tobramycin by BAUSCH AND LOMB INC on November 29^th, 1993.

Summary for BETHKIS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	2
Drug Prices:	Drug price information for BETHKIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BETHKIS
What excipients (inactive ingredients) are in BETHKIS?	BETHKIS excipients list
DailyMed Link:	BETHKIS at DailyMed

See drug prices for BETHKIS

Recent Clinical Trials for BETHKIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cystic Fibrosis Foundation Therapeutics
Novartis Pharmaceuticals
Cystic Fibrosis Foundation

See all BETHKIS clinical trials

Pharmacology for BETHKIS

Drug Class

Aminoglycoside Antibacterial

Paragraph IV (Patent) Challenges for BETHKIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BETHKIS	Inhalation Solution	tobramycin	300 mg/4 mL	201820	1	2017-08-31

US Patents and Regulatory Information for BETHKIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	BETHKIS	tobramycin	SOLUTION;INHALATION	201820-001	Oct 12, 2012	AN	RX	Yes	Yes

Expired US Patents for BETHKIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	BETHKIS	tobramycin	SOLUTION;INHALATION	201820-001	Oct 12, 2012	6,987,094
Chiesi	BETHKIS	tobramycin	SOLUTION;INHALATION	201820-001	Oct 12, 2012	7,939,502
Chiesi	BETHKIS	tobramycin	SOLUTION;INHALATION	201820-001	Oct 12, 2012	7,696,178

EU/EMA Drug Approvals for BETHKIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Healthcare Limited	Tobi Podhaler	tobramycin	EMEA/H/C/002155Tobi Podhaler is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis. See sections 4.4 and 5.1 regarding data in different age groups.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2011-07-20
Pari Pharma GmbH	Vantobra (previously Tobramycin PARI)	tobramycin	EMEA/H/C/005086Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2019-02-18
Pari Pharma GmbH	Vantobra	tobramycin	EMEA/H/C/002633Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Withdrawn	no	no	no	2015-03-18

International Patents for BETHKIS

See the table below for patents covering BETHKIS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	267591
Australia	2002319226
Bulgaria	108475
Bulgaria	66328
Brazil	0211320

Supplementary Protection Certificates for BETHKIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1273292	C01273292/01	Switzerland		PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
1280520	C300722	Netherlands		PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
1280520	CA 2015 00017	Denmark		PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
1280520	92678	Luxembourg		PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
1280520	300722	Netherlands		PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720

Last updated: June 7, 2026

Bethkis (tobramycin inhalation solution) market dynamics and financial trajectory: sales, pricing, exclusivity, and competitive pressure

Bethkis (tobramycin inhalation solution) sits in the chronic, high-cost cystic fibrosis (CF) antibiotic segment dominated by recurring inhaled therapy cycles. The commercial trajectory is shaped by (1) CF population growth and care centers, (2) prescribing persistence to inhaled antibiotics, (3) payer prior authorization and step edits versus alternative inhaled tobramycin/betamethasone regimens, (4) competition from lower-cost or differently positioned CF inhaled therapies, and (5) patent and exclusivity timing that affects generic entry and discounting behavior.

Because Bethkis is an inhaled antibiotic marketed for CF, its financial profile is typically “chronic and recurring” rather than acute. Demand is driven by CF prevalence and adherence to on/off inhaled cycle regimens, while revenue volatility is mainly driven by payer contracting, channel inventory, and competitive substitution within inhaled CF antibiotic classes.

---

How has Bethkis sales performed over time and what financial trajectory should investors model?

Short answer: Model Bethkis as recurring, unit-driven inhalation therapy with revenue largely tied to (a) CF patient counts eligible for inhaled antibiotics, (b) persistence to on/off dosing cycles, and (c) net price after rebates and contracting. The financial trajectory is usually stable until a major competitive or exclusivity event triggers discounting and channel share shifts.

Revenue drivers for Bethkis-like CF inhaled antibiotics

• CF eligible population: Treatable patients with chronic Pseudomonas aeruginosa colonization.
• Cycle adherence: The core inhaled regimen uses cycles (commonly 28 days on and 28 days off for inhaled tobramycin in CF). Adherence governs prescription fill volume.
• Center prescribing behavior: CF centers standardize protocols by guideline and historical payer coverage.
• Payer contracting: Managed care net pricing often compresses when at least one payer-friendly alternative is available.
• Channel dynamics: Inhaled antibiotics can show inventory swings around pricing changes and competitor launches.

What typically determines “financial trajectory inflection”

For Bethkis, modeled inflection points tend to be:

• launch of a lower net-price alternative (including generics or authorized equivalents),
• major payer policy shifts (step edits to different inhaled products),
• changes in CF treatment guidelines or sequencing that de-emphasize inhaled tobramycin in favor of other classes, and
• supply disruptions or tender wins.

Competitive substitution mechanics to incorporate in the model

In CF inhaled therapy, substitution is rarely “therapeutic class neutral.” It depends on:

• prior authorization criteria,
• payer willingness to cover specific inhaled devices and formulations,
• patient tolerance to inhaled delivery (device and formulation matters),
• clinical comfort with switching inhaled antibiotics in stable chronic colonization.

---

What are the key market dynamics affecting Bethkis demand in cystic fibrosis?

Short answer: Bethkis demand tracks chronic CF care intensity and payer coverage. The inhaled antibiotic market is sticky at the center level but price-sensitive once alternatives proliferate.

Dynamics by demand layer

1) Patient and clinician behavior

• Chronic dosing creates recurring demand, but changes in regimen occur during exacerbations, intolerance, or payer denials.
• CF clinicians manage inhaled antibiotics alongside other CF therapies (airway clearance, bronchodilators, mucolytics, and other anti-infectives), so substitution is often protocol-driven.

2) Payer and reimbursement

• Net price and formulary position are the main commercial levers.
• Prior authorization and quantity limits shape realized revenue even when list price stays flat.
• Payers often prefer an “included” inhaled option after they complete contracting and rebate negotiations.

3) Pricing and discounting

• When a lower-priced alternative gains formulary inclusion, incumbents often respond with rebates or contract concessions.
• In CF, multiple inhaled antibiotic and airway-related therapies compete in narrow patient windows.

---

What patent and exclusivity timeline governs Bethkis in the US and how does it impact generic pricing risk?

Short answer: Bethkis’s exclusivity and patent estate timing determine whether generic or authorized “equivalents” can enter without carve-out constraints. When exclusivity/patents expire or are successfully challenged, generic substitution usually drives rapid net price compression.

Exclusivity and patent-expiration impact (how it maps to commercial outcomes)

• Before expiration: Incumbent typically holds formulary stability with periodic price rises in nominal terms but usually with rebate pressure from competing inhaled therapies.
• At/after expiration: Expect formulary churn, increased payer price pressure, and higher share loss to generics or authorized versions if a device and formulation are treated as substitutable.
• Litigation outcomes: Settlement structures can delay launch dates and keep pricing higher for longer, depending on terms.

Patent estate coverage types investors should model for Bethkis

Inhaled formulation products typically face multiple patent layers:

• active ingredient use and dosing regimens,
• formulation composition (e.g., specific concentration and excipient system),
• manufacturing/process claims,
• delivery system or particle size/device-adjacent claims.

(These layers influence how “fast” generic entry translates into full substitution.)

---

What patents protect Bethkis, and how strong is the patent estate for Bethkis versus generic entry threats?

Short answer: The protective strength and “entry friction” depend on whether the relevant Orange Book-listed patents include formulation, method-of-use, and/or manufacturing claims that are hard to design around.

How patent strength translates into real commercial risk

• If key claims are narrow to formulation parameters, generics may still enter with a near-variant formulation, but substitution speed depends on payer acceptance and device interchangeability.
• If claims cover dosing schedules or specific CF patient subsets, method-of-use constraints can slow substitution even after launch.
• If manufacturing/process patents exist, the practical ability to scale at commercial quality can delay uptake.

---

What is the Orange Book status of Bethkis and which patents are listed for approval holders?

Short answer: Orange Book listing status and the specific listed patents (expiration dates and patent numbers) determine when generic applicants can file and whether a Paragraph IV challenge triggers a 30-month stay or other consequences.

Orange Book decision points that affect future revenue

• FDA approval date and listed exclusivity windows
• Patent expiration vs. patent challenge timing
• Whether patents are listed as expiring earlier but protected by other claims
• Whether multiple patents cover different aspects (drug product vs. method-of-use)

---

Are there Paragraph IV (or other) challenges against Bethkis, and what does litigation history imply for launch timing?

Short answer: If Paragraph IV challenges exist, their outcomes typically forecast:

• probability of an early generic entry,
• expected launch date window,
• settlement-driven “authorized delay,” and
• whether generics are likely to enter with a full-label or carve-out scope.

How to read litigation for commercial impact

• A settlement that includes “delayed launch” usually preserves incumbent revenue for the duration of the stay or term.
• A court outcome that narrows claims can accelerate a new product’s probability of being substituted by payers.

---

How does Bethkis compare with alternative inhaled tobramycin products and other CF anti-infectives on competitiveness and reimbursement?

Short answer: Bethkis competes in the “inhaled CF antibiotic” niche where payers compare net cost, formulary coverage, and interchangeability with other inhaled tobramycin offerings and different anti-Pseudomonas strategies.

Competitor comparison dimensions

• Net price and rebate structure: Biggest determinant of payer positioning.
• Device and administration time: Affects adherence and center workflow.
• Formulation substitution rules: Some payers require “same active, same dosage form, same device.”
• Clinical sequencing: Guidelines and local protocols decide whether tobramycin cycles remain preferred.

---

What generic entry risks exist for Bethkis, and what generic launch scenarios should be modeled?

Short answer: Generic entry risk is primarily driven by the timing and enforceability of Orange Book-listed patents plus litigation outcomes and settlement terms.

Generic launch scenario framework

Model three states:

1. No near-term entry: Bethkis maintains formulary position; revenue depends on CF growth and competitive discounting.
2. Authorized or generic entry with delay: Revenue holds longer; discounts accelerate after the entry window.
3. Non-stipulated entry on/soon after key expiration: Expect share loss and net price compression, with the incumbent’s revenue shrinking faster than patient-count growth.

---

What regulatory and manufacturing/IP barriers affect Bethkis continued commercialization?

Short answer: For inhaled antibiotics, the barriers are often tied to:

• device and drug product manufacturing controls,
• ability to show bioequivalence or equivalence for generic pathways,
• and whether formulation/device are considered substitutable.

Manufacturing and quality considerations that shape market share

• Inhaled formulations are sensitive to process parameters.
• Sustained supply is a key commercial driver in chronic regimens.
• Any supply constraints can cause prescribers to switch to alternatives, locking in payer behavior even after supply normalizes.

---

How do payer contracting trends and channel behavior influence Bethkis net revenue?

Short answer: Bethkis net revenue typically follows payer contract structure rather than list price. In chronic CF inhaled antibiotics, contracting dynamics often show “lumpy” changes around renewal cycles and formulary updates.

Commercial behavior patterns to anticipate

• Formulary tier migration: from preferred to non-preferred under competitive pricing pressure.
• Utilization management: step edits or quantity limits that cap early use until criteria are met.
• Rebate revisions: incumbents may grant higher rebates to prevent share loss during competitor launches.

---

Key Takeaways

• Bethkis commercial performance is driven by chronic CF treatment adherence and payer net pricing, not one-time acute demand.
• Market inflection points are typically tied to exclusivity/patent expiration, Orange Book listings, and litigation/settlement structures that determine when generic or equivalent products enter.
• Competitiveness in CF inhaled antibiotics depends on formulary inclusion, device interchangeability, and the ability to substitute across inhaled tobramycin products and alternative anti-Pseudomonas strategies.
• Generic entry risk should be modeled using three revenue states: no entry, delayed entry (authorized or settlement-driven), and near-term entry that triggers share and net price compression.

---

FAQs

1) What factors most affect Bethkis utilization in cystic fibrosis patients?

Patient adherence to inhaled cycle regimens, CF center protocol persistence, and payer authorization coverage are the main utilization drivers.

2) How quickly do CF inhaled antibiotic revenues typically shift after generic entry?

Net price compression and formulary churn usually begin immediately upon entry, but full share transfer depends on payer policies and prescriber willingness to switch inhaled regimens.

3) Does device or formulation difference change substitutability for Bethkis generics?

Yes. Payers may treat inhalation device characteristics and specific formulation parameters as substitution constraints, affecting how fast uptake occurs.

4) What litigation outcomes matter most for Bethkis commercial timing?

Settlement terms that delay launch and court decisions that uphold or narrow key Orange Book-listed claims determine the realistic launch calendar.

5) Where does most revenue “surprise” come from for Bethkis?

Rebate and contracting changes, formulary tier updates, and center-level persistence shifts after competitor launches or payer denials.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. Department of Health and Human Services).
2. FDA. Drug Approval and Databases (accessed via relevant product approval and labeling records). (U.S. Department of Health and Human Services).